title: The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.
abstract: Mucopolysaccharidosis (MPS) VII is a lysosomal storage disease due to deficient activity of β-glucuronidase (GUSB), and results in glycosaminoglycan accumulation. Skeletal manifestations include bone dysplasia, degenerative joint disease, and growth retardation. One gene therapy approach for MPS VII involves neonatal intravenous injection of a gamma retroviral vector expressing GUSB, which results in stable expression in liver and secretion of enzyme into blood at levels predicted to be similar or higher to enzyme replacement therapy. The goal of this study was to evaluate the long-term effect of neonatal gene therapy on skeletal manifestations in MPS VII dogs. Treated MPS VII dogs could walk throughout their lives, while untreated MPS VII dogs could not stand beyond 6 months and were dead by 2 years. Luxation of the coxofemoral joint and the patella, dysplasia of the acetabulum and supracondylar ridge, deep erosions of the distal femur, and synovial hyperplasia were reduced, and the quality of articular bone was improved in treated dogs at 6 to 11 years of age compared with untreated MPS VII dogs at 2 years or less. However, treated dogs continued to have osteophyte formation, cartilage abnormalities, and an abnormal gait. Enzyme activity was found near synovial blood vessels, and there was 2% as much GUSB activity in synovial fluid as in serum. We conclude that neonatal gene therapy reduces skeletal abnormalities in MPS VII dogs, but clinically-relevant abnormalities remain. Enzyme replacement therapy will probably have similar limitations long-term.
authors.affiliation: Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Xing
authors.forename: Van W
authors.initials: VW
authors.lastname: Knox
authors.forename: Patricia A
authors.initials: PA
authors.lastname: O'Donnell
authors.forename: Tracey
authors.initials: T
authors.lastname: Sikura
authors.forename: Yuli
authors.initials: Y
authors.lastname: Liu
authors.forename: Susan
authors.initials: S
authors.lastname: Wu
authors.forename: Margret L
authors.initials: ML
authors.lastname: Casal
authors.forename: Mark E
authors.initials: ME
authors.lastname: Haskins
authors.forename: Katherine P
authors.initials: KP
authors.lastname: Ponder
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D004285:Dogs; D005260:Female; D005270:Femur Head / Q000473:pathology; D015316:Genetic Therapy; D005966:Glucuronidase / Q000235:genetics* / Q000378:metabolism; D006614:Hindlimb / Q000473:pathology; D017746:Joint Capsule / Q000098:blood supply / Q000201:enzymology; D007596:Joints / Q000473:pathology; D008297:Male; D016538:Mucopolysaccharidosis VII / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D005966:Glucuronidase